Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is 10x Genomics (TXG) Stock Up +3.56% Today?

Why Is 10x Genomics (TXG) Stock Up +3.56% Today?

Key Takeaways

  • 10x Genomics shares gained 3.56% in midday trading Thursday, rising $2.03 to $59.10 from the prior close of $57.07.
  • The primary catalyst is fresh evidence of international commercial adoption of Atera, the company's whole-transcriptome spatial biology platform.
  • Novogene, one of Asia's largest sequencing service providers, formally added Atera to its spatial omics service lineup, with its first instrument arriving at its Tianjin lab.
  • Secondary drivers include a Korean channel partner's Atera showcase and continued follow-through from management's upbeat comments at a healthcare conference earlier this week.
  • The advance was company-specific: the broad market and close peers were flat to lower, including ILMN and QTRX.
  • News Significance Score: 24/100 — modest channel-expansion news paired with a move smaller than the stock's typical daily swing.
  • This is the third straight gain, lifting TXG off its Nov. 12 low of $53, though shares remain roughly 42% below October's 52-week high.
  • Traders are watching fourth-quarter Atera shipment cadence toward roughly 50 units and the expected step-down in gross margin to the low-60% range.
  • For deeper detail on Price Targets, Earnings and Forecast pages, explore the dedicated ticker resources.
  • Readers can also review Trending AI Robots for AI-driven strategy ideas across current market conditions.

Opening Summary

10x Genomics, Inc. (Nasdaq: TXG) is a Pleasanton, California-based life science technology company that sells instruments, consumables and software for single-cell and spatial biology research, used across oncology, immunology and neuroscience. On Thursday, the stock rose 3.56%, trading at $59.10 against the previous session's close of $57.07 — a gain of $2.03. The direction was clearly positive, and the move was tied to verifiable company news: a large Asian service provider began offering the company's flagship Atera platform, reinforcing the commercial ramp narrative that has driven shares higher throughout 2026.

Atera Adoption Expands Across Asia

The clearest driver was Novogene's announcement that it has formally integrated the Atera in-situ spatial platform into its single-cell and spatial omics service offering, with the first instrument arriving at its Tianjin facility on the same day. As one of the first service providers to carry the platform, Novogene can now deliver whole-transcriptome spatial work at scale — more than 18,000 protein-coding genes per slide and capacity for hundreds of samples annually — giving 10x a delivery channel into Chinese academic and translational research budgets without requiring institutions to buy instruments outright.

A second, smaller item came from Korea, where partner DowBiomedica said it presented Atera at the AACR-KCA international cancer conference hosted in Gyeongju, marketing the platform's tumor-microenvironment applications to regional researchers. Neither release disclosed financial terms, which limits their materiality relative to a company with a market capitalization near $7.8 billion.

Follow-Through From Conference Commentary

Thursday's gain extends momentum built earlier in the week, when management told investors at a Jefferies healthcare conference that Atera demand continues to outrun supply, that more than half of early orders are coming from customers who did not previously own a Xenium system, and that shipments should scale toward roughly 50 instruments per quarter from the first quarter. Management reiterated a 2026 target of about 50 Atera units and pointed to field-service and installation capacity as the binding constraint rather than demand. That message has supported three consecutive up sessions.

Earnings Aftermath and the Analyst Backdrop

The rebound is unfolding against a sharp reset. Third-quarter revenue of $150.7 million beat expectations and full-year guidance was raised to $625–635 million, but a warning that gross margin would compress as lower-margin instrument shipments ramp drove a steep October and early-November selloff. Several firms trimmed targets after the report, and the consensus stance remains cautious with an average target near $68. Thursday's news chips away at the bear case without resolving the margin debate.

Market Context and Trading Activity

The move was idiosyncratic. The S&P 500 proxy slipped about 0.9% and the biotech benchmark XBI was roughly flat, while the genomics-focused ARKG eased modestly. Close peer Illumina fell nearly 2%, and Quanterix extended a steep two-day collapse, so 10x's gain was not sector sympathy.

Volume has been running below the roughly 1.7 million-share 20-day average across recent sessions, suggesting a thin, sentiment-driven advance rather than institutional accumulation. The stock has reclaimed its short-term moving averages after bottoming at $53 on Nov. 12, but it remains far below the $102.81 peak set in early October and well under the $68 consensus target.

News Significance Score

The score runs from 0 — no meaningful news and a price move that is routine for the stock — to 100, reserved for transformative news combined with an extreme, rare move. This event scores 24 out of 100. The verified news is real but moderate: a service-provider distribution win and a regional marketing appearance, both without disclosed revenue, are incremental to a multi-billion-dollar business rather than transformational. Nor was the price action unusual. The 3.56% advance was smaller than the stock's average daily move of about 4.2% over the past 60 sessions, and moves of that size or larger occurred 26 times in that window. Strong news and an ordinary move combine to a modest score.

What Comes Next for TXG

Attention now turns to fourth-quarter execution. Investors will look for confirmation that Atera shipments are tracking toward roughly 50 units for 2026 and that installations are converting into recurring consumables revenue rather than one-time instrument sales. The margin trajectory is the key tension: management guided fourth-quarter gross margin into the low-60% range, and any shortfall would revive valuation concerns. Full-year 2027 guidance, likely delivered with the fourth-quarter report in February, will be the next major catalyst. Additional service-provider wins in China and Korea, further peer data points from Illumina and Quanterix, and the funding environment for academic and government research budgets all remain swing factors, alongside the risk that manufacturing or field-service bottlenecks delay the ramp.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the specific symbols they trade, so the page offers a practical starting point for comparing approaches rather than a single template. For readers tracking volatile life-science names like this one, reviewing the featured bots is a sensible next step.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TXG

TXG in downward trend: price dove below 50-day moving average on October 30, 2026

TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 73 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 32 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for TXG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 212 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.142). P/E Ratio (-100.475) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -16%. ICCM experienced the highest price growth at 42%, while LFWD experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a life science technology company, which engages in building products to interrogate, understand and master biology

Industry MedicalNursingServices

Industry
N/A
Address
6230 Stoneridge Mall Road
Phone
+1 925 401-7300
Employees
1178
Web
https://www.10xgenomics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
Why Is 10x Genomics (TXG) Stock Up +3.56% Today?